Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC – Get Free Report) saw a large decline in short interest during the month of June. As of June 30th, there was short interest totaling 12,043 shares, a decline of 57.9% from the June 15th total of 28,598 shares. Currently, 0.0% of the shares of the stock are short sold. Based on an average daily trading volume, of 43,196 shares, the days-to-cover ratio is presently 0.3 days.
Hedge Funds Weigh In On Oaktree Acquisition Corp. III Life Sciences
Institutional investors and hedge funds have recently bought and sold shares of the stock. Goldman Sachs Group Inc. purchased a new stake in shares of Oaktree Acquisition Corp. III Life Sciences during the first quarter valued at approximately $5,417,000. Moore Capital Management LP purchased a new position in shares of Oaktree Acquisition Corp. III Life Sciences in the second quarter worth $5,502,000. Millennium Management LLC bought a new stake in Oaktree Acquisition Corp. III Life Sciences during the 1st quarter valued at $4,848,000. Lighthouse Investment Partners LLC boosted its position in Oaktree Acquisition Corp. III Life Sciences by 88.9% during the 2nd quarter. Lighthouse Investment Partners LLC now owns 850,000 shares of the company’s stock valued at $8,882,000 after buying an additional 400,000 shares during the period. Finally, Sculptor Capital LP boosted its position in Oaktree Acquisition Corp. III Life Sciences by 100.0% during the 2nd quarter. Sculptor Capital LP now owns 500,000 shares of the company’s stock valued at $5,225,000 after buying an additional 250,000 shares during the period.
Wall Street Analyst Weigh In
Separately, Weiss Ratings reiterated a “sell (d)” rating on shares of Oaktree Acquisition Corp. III Life Sciences in a research report on Tuesday, June 30th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the company presently has a consensus rating of “Sell”.
Oaktree Acquisition Corp. III Life Sciences Stock Performance
NASDAQ OACC opened at $10.70 on Thursday. The company has a 50-day simple moving average of $10.69 and a two-hundred day simple moving average of $10.66. Oaktree Acquisition Corp. III Life Sciences has a 12-month low of $10.30 and a 12-month high of $10.74.
Oaktree Acquisition Corp. III Life Sciences Company Profile
Oaktree Acquisition Corp. III Life Sciences (NASDAQ: OACC) is a special purpose acquisition company (“SPAC”) formed to pursue merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combinations with one or more businesses in the life sciences sector. Incorporated as a Cayman Islands exempted company, OACC is sponsored by Oaktree Capital Management, a global alternative investment firm with a longstanding track record in credit strategies and private equity.
Further Reading
- Five stocks we like better than Oaktree Acquisition Corp. III Life Sciences
- Cintas Keeps Beating Expectations—And the Story Isn’t Over
- Which Storage Stock Is Best Positioned to Win the AI Memory War?
- Tesla’s Delivery Surprise Was Big—Earnings Need to Be Bigger
- Why Johnson & Johnson’s Earnings Dip Looks Like a Buying Opportunity
Receive News & Ratings for Oaktree Acquisition Corp. III Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oaktree Acquisition Corp. III Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
